Exagen Inc. (XGN)

NASDAQ: XGN · IEX Real-Time Price · USD
1.900
0.00 (0.00%)
Jun 25, 2024, 11:12 AM EDT - Market open
0.00%
Market Cap 33.53M
Revenue (ttm) 55.73M
Net Income (ttm) -19.36M
Shares Out 17.37M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,333
Open 1.873
Previous Close 1.900
Day's Range 1.873 - 1.910
52-Week Range 1.300 - 3.043
Beta 1.30
Analysts Buy
Price Target 7.00 (+268.42%)
Earnings Date Aug 5, 2024

About XGN

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlap... [Read more]

Sector Healthcare
IPO Date Sep 19, 2019
Employees 174
Stock Exchange NASDAQ
Ticker Symbol XGN
Full Company Profile

Financial Performance

In 2023, Exagen's revenue was $52.55 million, an increase of 15.33% compared to the previous year's $45.56 million. Losses were -$23.69 million, -50.01% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for XGN stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(268.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors' minds. This is because investors often opt for the stock-picking approach that inv...

Other symbols: AMCAPDNHCATYOU
14 days ago - Benzinga

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024.

6 weeks ago - GlobeNewsWire

Exagen to Announce First Quarter 2024 Results on May 13, 2024

CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before th...

7 weeks ago - GlobeNewsWire

Exagen Inc. Announces Changes to the Board of Directors

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.

2 months ago - GlobeNewsWire

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full yea...

3 months ago - GlobeNewsWire

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Lif...

3 months ago - GlobeNewsWire

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 202...

3 months ago - GlobeNewsWire

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for th...

6 months ago - GlobeNewsWire

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September...

8 months ago - GlobeNewsWire

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the executi...

8 months ago - GlobeNewsWire

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, aft...

8 months ago - GlobeNewsWire

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 Am...

9 months ago - GlobeNewsWire

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald...

10 months ago - GlobeNewsWire

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023.

11 months ago - GlobeNewsWire

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 43rd Annual Growt...

11 months ago - GlobeNewsWire

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before t...

11 months ago - GlobeNewsWire

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen B...

1 year ago - GlobeNewsWire

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43r d Annual Growth St...

1 year ago - GlobeNewsWire

Exagen Inc. Reports First Quarter 2023 Results

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 20...

1 year ago - GlobeNewsWire

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 Record AVISE® CTD Volume in 2022

1 year ago - GlobeNewsWire

Exagen Inc. to Participate in Upcoming March Conferences

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March inve...

1 year ago - GlobeNewsWire

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life ...

1 year ago - GlobeNewsWire

Exagen Inc. Elects Tina S. Nova, Ph.D.

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair...

1 year ago - GlobeNewsWire

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, aft...

1 year ago - GlobeNewsWire

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.  Longtime CEO and President Ron Rocca, who took...

1 year ago - GlobeNewsWire